Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

Prothrombin time (PT) is a measure of coagulation status and was assessed in the majority of patients in the rivaroxaban phase II and III clinical trials as a pharmacodynamic marker. In the absence of sufficient phase III pharmacokinetic (PK) data to provide individual exposure measures for input in...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Alexander Solms (Yazar), Matthias Frede (Yazar), Scott D. Berkowitz (Yazar), Anne Hermanowski‐Vosatka (Yazar), Dagmar Kubitza (Yazar), Wolfgang Mueck (Yazar), Theodore E. Spiro (Yazar), Stefan Willmann (Yazar), Xiaoyu Yan (Yazar), Liping Zhang (Yazar), Dirk Garmann (Yazar)
Materyal Türü: Kitap
Baskı/Yayın Bilgisi: Wiley, 2019-11-01T00:00:00Z.
Konular:
Online Erişim:Connect to this object online.
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Internet

Connect to this object online.

3rd Floor Main Library

Detaylı Erişim Bilgileri 3rd Floor Main Library
Yer Numarası: A1234.567
Kopya Bilgisi 1 Kütüphanede